163 related articles for article (PubMed ID: 33338846)
1. Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2
Zhou L; Feng Y; Ma YC; Zhang Z; Wu JW; Du S; Li WY; Lu XH; Ma Y; Wang RL
J Mol Graph Model; 2021 Mar; 103():107807. PubMed ID: 33338846
[TBL] [Abstract][Full Text] [Related]
2. Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain-containing protein tyrosine phosphatase (SHP2) inhibitor at molecular level through molecular docking and molecular dynamics.
Wang RR; Liu WS; Zhou L; Ma Y; Wang RL
J Biomol Struct Dyn; 2020 Mar; 38(5):1525-1538. PubMed ID: 31043123
[TBL] [Abstract][Full Text] [Related]
3. Exploring the cause of the dual allosteric targeted inhibition attaching to allosteric sites enhancing SHP2 inhibition.
Yangchun M; WenYu Y; Liang Z; LiPeng L; JingWei W; WeiYa L; Shan D; Ying M; RunLing W
Mol Divers; 2022 Jun; 26(3):1567-1580. PubMed ID: 34338914
[TBL] [Abstract][Full Text] [Related]
4. Study on the allosteric activation mechanism of SHP2
Liu L; Cheng Y; Zhang Z; Li J; Geng Y; Li Q; Luo D; Liang L; Liu W; Hu J; Ouyang W
Phys Chem Chem Phys; 2023 Sep; 25(35):23588-23601. PubMed ID: 37621251
[TBL] [Abstract][Full Text] [Related]
5. Gain-of-Function SHP2 E76Q Mutant Rescuing Autoinhibition Mechanism Associated with Juvenile Myelomonocytic Leukemia.
Rehman AU; Rafiq H; Rahman MU; Li J; Liu H; Luo S; Arshad T; Wadood A; Chen HF
J Chem Inf Model; 2019 Jul; 59(7):3229-3239. PubMed ID: 31244092
[TBL] [Abstract][Full Text] [Related]
6. Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2
Du S; Lu XH; Li WY; Li LP; Ma YC; Zhou L; Wu JW; Ma Y; Wang RL
Mol Divers; 2021 Aug; 25(3):1873-1887. PubMed ID: 33392964
[TBL] [Abstract][Full Text] [Related]
7. An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase.
Anselmi M; Hub JS
Sci Rep; 2020 Oct; 10(1):18530. PubMed ID: 33116231
[TBL] [Abstract][Full Text] [Related]
8. Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study.
Li HL; Ma Y; Zheng CJ; Jin WY; Liu WS; Wang RL
J Biomol Struct Dyn; 2018 Nov; 36(14):3856-3868. PubMed ID: 29125030
[TBL] [Abstract][Full Text] [Related]
9. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
[TBL] [Abstract][Full Text] [Related]
10. A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors.
Song Y; Zhao M; Wu Y; Yu B; Liu HM
Acta Pharm Sin B; 2021 Mar; 11(3):750-762. PubMed ID: 33777680
[TBL] [Abstract][Full Text] [Related]
11. Exploring the reason for increased activity of SHP2 caused by D61Y mutation through molecular dynamics.
Wang RR; Ma Y; Du S; Li WY; Sun YZ; Zhou H; Wang RL
Comput Biol Chem; 2019 Feb; 78():133-143. PubMed ID: 30508783
[TBL] [Abstract][Full Text] [Related]
12. Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
Anselmi M; Calligari P; Hub JS; Tartaglia M; Bocchinfuso G; Stella L
J Chem Inf Model; 2020 Jun; 60(6):3157-3171. PubMed ID: 32395997
[TBL] [Abstract][Full Text] [Related]
13. Exploring the Distinct Binding and Activation Mechanisms for Different CagA Oncoproteins and SHP2 by Molecular Dynamics Simulations.
Wang Q; Zhao WC; Fu XQ; Zheng QC
Molecules; 2021 Feb; 26(4):. PubMed ID: 33562680
[TBL] [Abstract][Full Text] [Related]
14. The loops of the N-SH2 binding cleft do not serve as allosteric switch in SHP2 activation.
Anselmi M; Hub JS
Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33888588
[TBL] [Abstract][Full Text] [Related]
15. Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome.
Martinelli S; Nardozza AP; Delle Vigne S; Sabetta G; Torreri P; Bocchinfuso G; Flex E; Venanzi S; Palleschi A; Gelb BD; Cesareni G; Stella L; Castagnoli L; Tartaglia M
J Biol Chem; 2012 Aug; 287(32):27066-77. PubMed ID: 22711529
[TBL] [Abstract][Full Text] [Related]
16. Investigating the reason for loss-of-function of Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) caused by Y279C mutation through molecular dynamics simulation.
Liu WS; Wang RR; Li WY; Rong M; Liu CL; Ma Y; Wang RL
J Biomol Struct Dyn; 2020 Jun; 38(9):2509-2520. PubMed ID: 31258001
[TBL] [Abstract][Full Text] [Related]
17. Probing the Dynamic Mechanism of Uncommon Allosteric Inhibitors Optimized to Enhance Drug Selectivity of SHP2 with Therapeutic Potential for Cancer Treatment.
Farrokhzadeh A; Akher FB; Soliman MES
Appl Biochem Biotechnol; 2019 May; 188(1):260-281. PubMed ID: 30430347
[TBL] [Abstract][Full Text] [Related]
18. Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state.
Calligari P; Santucci V; Stella L; Bocchinfuso G
Comput Struct Biotechnol J; 2021; 19():6125-6139. PubMed ID: 34900129
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel SHP2 allosteric inhibitor using virtual screening, FMO calculation, and molecular dynamic simulation.
Yuan Z; Zhang M; Chang L; Chen X; Ruan S; Shi S; Zhang Y; Zhu L; Li H; Li S
J Mol Model; 2024 Apr; 30(5):131. PubMed ID: 38613643
[TBL] [Abstract][Full Text] [Related]
20. Scaffold-based selective SHP2 inhibitors design using core hopping, molecular docking, biological evaluation and molecular simulation.
Li WY; Ma Y; Li HX; Lu XH; Du S; Ma YC; Zhou L; Wang RL
Bioorg Chem; 2020 Dec; 105():104391. PubMed ID: 33113413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
